Tanya Turan to Stents
This is a "connection" page, showing publications Tanya Turan has written about Stents.
Connection Strength
3.615
-
Impact of Baseline Features and Risk Factor Control on Cognitive Function in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial. Cerebrovasc Dis. 2019; 47(1-2):24-31.
Score: 0.456
-
Is There Benefit from Stenting on Cognitive Function in Intracranial Atherosclerosis? Cerebrovasc Dis. 2017; 43(1-2):31-35.
Score: 0.389
-
Yet again no benefit of stenting over medical therapy. Lancet Neurol. 2015 Jun; 14(6):565-6.
Score: 0.350
-
Intracranial stenosis: impact of randomized trials on treatment preferences of US neurologists and neurointerventionists. Cerebrovasc Dis. 2014; 37(3):203-11.
Score: 0.322
-
Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):e51-60.
Score: 0.291
-
The CASSISS Randomized Clinical Trial. Stroke. 2023 01; 54(1):286-289.
Score: 0.148
-
Relationship between Risk Factor Control and Compliance with a Lifestyle Modification Program in the Stenting Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis Trial. J Stroke Cerebrovasc Dis. 2018 Mar; 27(3):801-805.
Score: 0.105
-
Nonprocedural Symptomatic Infarction and In-Stent Restenosis After Intracranial Angioplasty and Stenting in the SAMMPRIS Trial (Stenting and Aggressive Medical Management for the Prevention of Recurrent Stroke in Intracranial Stenosis). Stroke. 2017 06; 48(6):1501-1506.
Score: 0.101
-
Relationship between risk factor control and vascular events in the SAMMPRIS trial. Neurology. 2017 Jan 24; 88(4):379-385.
Score: 0.098
-
Impact of the New American Heart Association/American Stroke Association Definition of Stroke on the Results of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial. J Stroke Cerebrovasc Dis. 2017 Jan; 26(1):108-115.
Score: 0.097
-
Frequency, Risk Factors, and Outcome of Coexistent Small Vessel Disease and Intracranial Arterial Stenosis: Results From the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial. JAMA Neurol. 2016 Jan; 73(1):36-42.
Score: 0.092
-
Enrollment volume effect on risk factor control and outcomes in the SAMMPRIS trial. Neurology. 2015 Dec 15; 85(24):2090-7.
Score: 0.091
-
Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis? Stroke. 2015 Nov; 46(11):3282-4.
Score: 0.090
-
Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis. Stroke. 2015 Mar; 46(3):775-9.
Score: 0.086
-
Comparison of endovascular treatment approaches for acute ischemic stroke: cost effectiveness, technical success, and clinical outcomes. J Neurointerv Surg. 2015 Sep; 7(9):666-70.
Score: 0.083
-
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014 Jan 25; 383(9914):333-41.
Score: 0.079
-
Intracranial stenting: SAMMPRIS. Stroke. 2013 Jun; 44(6 Suppl 1):S41-4.
Score: 0.077
-
Mechanisms of stroke after intracranial angioplasty and stenting in the SAMMPRIS trial. Neurosurgery. 2013 May; 72(5):777-95; discussion 795.
Score: 0.076
-
Response to critique of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial by Abou-Chebl and Steinmetz. Stroke. 2012 Oct; 43(10):2806-9.
Score: 0.073
-
Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). Stroke. 2012 Oct; 43(10):2682-8.
Score: 0.073
-
Impact of operator and site experience on outcomes after angioplasty and stenting in the SAMMPRIS trial. J Neurointerv Surg. 2013 Nov; 5(6):528-33.
Score: 0.073
-
Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15; 365(11):993-1003.
Score: 0.068
-
Design of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial. J Stroke Cerebrovasc Dis. 2011 Jul-Aug; 20(4):357-68.
Score: 0.067
-
Current status of the management of symptomatic intracranial atherosclerotic disease: the rationale for a randomized trial of medical therapy and intracranial stenting. J Neurointerv Surg. 2009 Jul; 1(1):35-9.
Score: 0.058
-
Treatment of atherosclerotic intracranial arterial stenosis. Stroke. 2009 Jun; 40(6):2257-61.
Score: 0.058
-
Treatment of intracranial atherosclerotic stenosis. Rev Neurol Dis. 2008; 5(3):117-24.
Score: 0.053
-
Dual Antiplatelet Therapy Beyond 90 days in Symptomatic Intracranial Stenosis in the SAMMPRIS Trial. J Stroke Cerebrovasc Dis. 2020 Dec; 29(12):105254.
Score: 0.032
-
Submaximal Angioplasty for Symptomatic Intracranial Atherosclerotic Disease: A Meta-Analysis of Peri-Procedural and Long-Term Risk. Neurosurgery. 2020 06 01; 86(6):755-762.
Score: 0.031